399 related articles for article (PubMed ID: 19558920)
1. [Sequential histological and immunohistochemical assessment of proliferation and apoptotic markers during treatment of psoriasis with antitumor necrosis factor alpha (infliximab)].
Gómez-Mateo C; Avalos-Peralta SP; Ríos-Martín JJ; Carrizosa-Esquivel AM; González-Cámpora R; Camacho-Martínez F
Actas Dermosifiliogr; 2009 Jun; 100(5):420-4. PubMed ID: 19558920
[TBL] [Abstract][Full Text] [Related]
2. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy.
Markham T; Mullan R; Golden-Mason L; Rogers S; Bresnihan B; Fitzgerald O; Fearon U; Veale DJ
J Am Acad Dermatol; 2006 Jun; 54(6):1003-12. PubMed ID: 16713454
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy.
Markham T; Mathews C; Rogers S; Mullan R; Bresnihan B; Fitzgerald O; Veale DJ; Fearon U
Br J Dermatol; 2006 Dec; 155(6):1191-6. PubMed ID: 17107388
[TBL] [Abstract][Full Text] [Related]
4. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis.
Krüger-Krasagakis S; Galanopoulos VK; Giannikaki L; Stefanidou M; Tosca AD
Br J Dermatol; 2006 Mar; 154(3):460-6. PubMed ID: 16445776
[TBL] [Abstract][Full Text] [Related]
5. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
[TBL] [Abstract][Full Text] [Related]
6. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.
Goedkoop AY; Kraan MC; Picavet DI; de Rie MA; Teunissen MB; Bos JD; Tak PP
Arthritis Res Ther; 2004; 6(4):R326-34. PubMed ID: 15225368
[TBL] [Abstract][Full Text] [Related]
7. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.
Goedkoop AY; Kraan MC; Teunissen MB; Picavet DI; de Rie MA; Bos JD; Tak PP
Ann Rheum Dis; 2004 Jul; 63(7):769-73. PubMed ID: 15194570
[TBL] [Abstract][Full Text] [Related]
8. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
[TBL] [Abstract][Full Text] [Related]
9. The role of lesional T cells in recalcitrant psoriasis during infliximab therapy.
Bovenschen HJ; Van De Kerkhof PC; Gerritsen WJ; Seyger MM
Eur J Dermatol; 2005; 15(6):454-8. PubMed ID: 16280298
[TBL] [Abstract][Full Text] [Related]
10. Infliximab restores the balance between pro- and anti-apoptotic proteins in regressing psoriatic lesions.
Kokolakis G; Giannikaki E; Stathopoulos E; Avramidis G; Tosca AD; Krüger-Krasagakis S
Br J Dermatol; 2012 Mar; 166(3):491-7. PubMed ID: 21985184
[TBL] [Abstract][Full Text] [Related]
11. Influence of infliximab on keratinocyte apoptosis in psoriasis patients.
Raho G; Vena GA; Bizzoca A; Cassano N; Garofalo E; Congedo M; Gennarini G
Immunopharmacol Immunotoxicol; 2011 Mar; 33(1):227-31. PubMed ID: 20507213
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of lymphocyte populations in psoriatic plaques following inhibition of tumor necrosis factor alpha with etanercept].
Mahiques L; Pitarch G; Sánchez-Carazo JL; Pérez-Ferriols A; Soriano CJ; Alegre V
Actas Dermosifiliogr; 2007 Oct; 98(8):539-44. PubMed ID: 17919428
[TBL] [Abstract][Full Text] [Related]
13. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo.
Kalb RE; Gurske J
J Am Acad Dermatol; 2005 Oct; 53(4):616-22. PubMed ID: 16198781
[TBL] [Abstract][Full Text] [Related]
14. Infliximab monotherapy in psoriasis: a case of rapid clinical and histological response.
Vincek V; Jacob SE; Nassiri M; Herbert LM; Nadji M; Kerdel FA
Int J Dermatol; 2004 Apr; 43(4):303-8. PubMed ID: 15090021
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis.
Lago E; Carneiro S; Cuzzi T; Magalhães G; Cássia F; Pessanha F; Ramos-e-Silva M
J Cutan Pathol; 2007 Jan; 34(1):15-21. PubMed ID: 17214849
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
[TBL] [Abstract][Full Text] [Related]
17. Cellular and molecular effects of pulsed dye laser and local narrow-band UVB therapy in psoriasis.
Rácz E; de Leeuw J; Baerveldt EM; Kant M; Neumann HA; van der Fits L; Prens EP
Lasers Surg Med; 2010 Mar; 42(3):201-10. PubMed ID: 20333742
[TBL] [Abstract][Full Text] [Related]
18. Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade.
Winterfield L; Menter A
Dermatol Clin; 2004 Oct; 22(4):437-47, ix. PubMed ID: 15450339
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
Puig L
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
[TBL] [Abstract][Full Text] [Related]
20. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression.
Benoit S; Toksoy A; Bröcker EB; Gillitzer R; Goebeler M
Br J Dermatol; 2004 May; 150(5):1009-12. PubMed ID: 15149518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
